

Amendment Statement of Principles concerning HYPOPITUITARISM (Reasonable Hypothesis) (No. 53 of 2022)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 29 April 2022

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Terence Campbell AM Chairperson

Contents

| 1 | Name | 3 |
|---|--------------|---|
| 2 | Commencement | 3 |
| 3 | Authority | 3 |
| 4 | Amendment | 3 |

1 Name

This is the Amendment Statement of Principles concerning *hypopituitarism* (*Reasonable Hypothesis*) (No. 53 of 2022).

2 Commencement

This instrument commences on 30 May 2022.

3 Authority

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

4 Amendment

The Statement of Principles concerning *hypopituitarism (Reasonable Hypothesis)* (No. 11 of 2019) (Federal Register of Legislation No. F2019L00009) is amended in the following manner:

| Section | Amendment |
|----------------------------|---|
| 9(16) | <i>Replace the existing factor in subsection 9(16) with the following:</i> |
| | taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of hypopituitarism; |
| | Note: <i>immune checkpoint inhibitor</i> is defined in the Schedule 1 - Dictionary. |
| 9(34) | Replace the existing factor in subsection $9(34)$ with the following: |
| | taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of hypopituitarism; |
| | Note: <i>immune checkpoint inhibitor</i> is defined in the Schedule 1 - Dictionary. |
| Schedule 1 – Dictionary | <i>Replace the existing definition of "immune checkpoint inhibitor" with the following:</i> |
| | <i>immune checkpoint inhibitor</i> means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab. |